Алексей Александрович Аксарин
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Алексей Александрович Аксарин has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- S. M. Kopeyka
Surgut District Clinical Hospital
4 shared publications - Elena I. Rossokha
Altai Regional Oncological Dispensary
2 shared publications M. D. Ter-Ovanesov
RUDN University
2 shared publications- M.I. Antoshkina
Republican Oncological Dispensary of the Republic of Mordovia
2 shared publications - Mikhail Dmitrievich Ter-Ovanesov
The Russian University of Medicine; Nizhny Novgorod Regional Clinical Oncological Dispensary
2 shared publications - Nadezhda V. Leushina
S.G. Primushko Republican Clinical Oncology Dispensary
2 shared publications
Latest Publications
- 17 November 2026
- Published by Alfmed LLC in Medical alphabet
- No. 27
Adaptation of molecular genetic diagnostics for non-small cell lung cancer to the clinical and epidemiological characteristics of the Khanty-Mansiysk Autonomous District-Ugra
Relevance. The article presents the results of a comprehensive analysis of clinical, epidemiological, morphological, and anamnestic characteristics of 316 patients with non-small cell lung cancer (NSCLC), residents of the Khanty-Mansi Autonomous district – Yugra, in whom molecular genetic alterations were identified. Objective. To conduct a comprehensive analysis of clinical, morphological, demographic, and anamnestic (smoking history) parameters and duration of residence in the region in patients with NSCLC who have confirmed molecular genetic alterations, as well as to assess their differences from a reference group of patients in whom driver mutations have not been detected, in the territory of the Khanty-Mansi Autonomous district – Yugra. Materials and methods. The study included 316 cases of NSCLC registered at the oncology center based at the Surgut District Clinical Hospital during 2020–2023. All patients with morphologically verified NSCLC, regardless of stage and histological subtype, underwent testing of a panel of genetic markers including EGFR, ALK, ROS1, BRAF, ERBB2 (HER2), KRAS, MET, RET, NTRK1/2/3, and PD-L1 expression level was determined ( Conclusions. The study showed that genetic aberrations are most common in adenocarcinoma (34% of cases), whereas in other histotypes their proportion is only 6%. In the mutation structure, alterations in EGFR (15%) and KRAS (14%) genes predominate; ALK rearrangements (5%), HER2 amplification (3%), ROS1 rearrangements (2%), and BRAF mutations (1%) are less frequently recorded. Significant associations were established: in non-smoking patients and in adenocarcinoma, the risk of detecting EGFR, KRAS mutations and ALK rearrangement is significantly higher, whereas long-term residence in the region (≥30 years) is associated with a lower probability of detecting EGFR mutations and ALK rearrangement. PD-L1 expression status did not affect the frequency of the studied driver mutations. The obtained data indicate regional features of the molecular profile of NSCLC in Yugra, which substantiates the need to adapt diagnostic algorithms and therapeutic approaches taking into account local clinical and epidemiological conditions to improve the effectiveness of drug provision and personalize treatment.
- 17 November 2026
- Published by Alfmed LLC in Medical alphabet
- No. 27
Adaptation of molecular genetic diagnostics for non-small cell lung cancer to the clinical and epidemiological characteristics of the Khanty-Mansiysk Autonomous District-Ugra
Relevance. The article presents the results of a comprehensive analysis of clinical, epidemiological, morphological, and anamnestic characteristics of 316 patients with non-small cell lung cancer (NSCLC), residents of the Khanty-Mansi Autonomous district – Yugra, in whom molecular genetic alterations were identified. Objective. To conduct a comprehensive analysis of clinical, morphological, demographic, and anamnestic (smoking history) parameters and duration of residence in the region in patients with NSCLC who have confirmed molecular genetic alterations, as well as to assess their differences from a reference group of patients in whom driver mutations have not been detected, in the territory of the Khanty-Mansi Autonomous district – Yugra. Materials and methods. The study included 316 cases of NSCLC registered at the oncology center based at the Surgut District Clinical Hospital during 2020–2023. All patients with morphologically verified NSCLC, regardless of stage and histological subtype, underwent testing of a panel of genetic markers including EGFR, ALK, ROS1, BRAF, ERBB2 (HER2), KRAS, MET, RET, NTRK1/2/3, and PD-L1 expression level was determined ( Conclusions. The study showed that genetic aberrations are most common in adenocarcinoma (34% of cases), whereas in other histotypes their proportion is only 6%. In the mutation structure, alterations in EGFR (15%) and KRAS (14%) genes predominate; ALK rearrangements (5%), HER2 amplification (3%), ROS1 rearrangements (2%), and BRAF mutations (1%) are less frequently recorded. Significant associations were established: in non-smoking patients and in adenocarcinoma, the risk of detecting EGFR, KRAS mutations and ALK rearrangement is significantly higher, whereas long-term residence in the region (≥30 years) is associated with a lower probability of detecting EGFR mutations and ALK rearrangement. PD-L1 expression status did not affect the frequency of the studied driver mutations. The obtained data indicate regional features of the molecular profile of NSCLC in Yugra, which substantiates the need to adapt diagnostic algorithms and therapeutic approaches taking into account local clinical and epidemiological conditions to improve the effectiveness of drug provision and personalize treatment.
- 30 October 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (5)
Clinical and demographic characteristics and treatment outcomes of patients with HR+/HER2– advanced breast cancer receiving ribociclib in standard clinical practice in Russia: interim results of the PROSPERITY study
Objective. To describe the clinical and demographic characteristics and to assess the effectiveness and safety of ribociclib combined with endocrine therapy (ET) in patients with HR+/HER2– advanced breast cancer (ABC) in Russian clinical practice settings, as part of the PROSPERITY observational study. Materials and methods. At the date of the interim analysis (October 31, 2024), the PROSPERITY study had enrolled 2.390 patients with HR+/HER2– ABC receiving ribociclib, alpelisib, ET, or chemotherapy as part of standard clinical practice in Russia. The ribociclib group comprised 1.468 patients (61.4% of the total cohort). This article analyzes clinical and demographic characteristics, time to treatment failure (TTF), progression-free survival (PFS), overall survival (OS), time to chemotherapy (TTC), and the safety profile of ribociclib. The index date was defined as the date of initiation of ribociclib therapy during the study enrollment period. Results. The median age of patients in the ribociclib arm was 59.0 years. The majority of patients received ribociclib as first-line (63.0%) or second-line (21.9%) therapy. The median TTF was 17.2 months (95% CI 16.1–18.4), and the median PFS was 20.3 months (95% CI 18.8–21.5). Median PFS was 24.3 months for first-line therapy, 16.0 months for second-line, 13.4 months for third-line, and 8.6 months for fourth and subsequent lines. Median OS and median TTC were not reached. Adverse events (AEs) were reported in 47.5% (723/1522) of patients; the most common were neutropenia (16.2%) and leukopenia (7.4%). The rate of treatment discontinuation due to AEs was low (5.9% of all patients in the ribociclib arm). Conclusion. The observational PROSPERITY study provided real-world data from Russia demonstrating ribociclib effectiveness and safety profiles generally comparable to results previously obtained in pivotal clinical trials.
- 30 October 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (5)
Clinical and demographic characteristics and treatment outcomes of patients with HR+/HER2– advanced breast cancer receiving ribociclib in standard clinical practice in Russia: interim results of the PROSPERITY study
Objective. To describe the clinical and demographic characteristics and to assess the effectiveness and safety of ribociclib combined with endocrine therapy (ET) in patients with HR+/HER2– advanced breast cancer (ABC) in Russian clinical practice settings, as part of the PROSPERITY observational study. Materials and methods. At the date of the interim analysis (October 31, 2024), the PROSPERITY study had enrolled 2.390 patients with HR+/HER2– ABC receiving ribociclib, alpelisib, ET, or chemotherapy as part of standard clinical practice in Russia. The ribociclib group comprised 1.468 patients (61.4% of the total cohort). This article analyzes clinical and demographic characteristics, time to treatment failure (TTF), progression-free survival (PFS), overall survival (OS), time to chemotherapy (TTC), and the safety profile of ribociclib. The index date was defined as the date of initiation of ribociclib therapy during the study enrollment period. Results. The median age of patients in the ribociclib arm was 59.0 years. The majority of patients received ribociclib as first-line (63.0%) or second-line (21.9%) therapy. The median TTF was 17.2 months (95% CI 16.1–18.4), and the median PFS was 20.3 months (95% CI 18.8–21.5). Median PFS was 24.3 months for first-line therapy, 16.0 months for second-line, 13.4 months for third-line, and 8.6 months for fourth and subsequent lines. Median OS and median TTC were not reached. Adverse events (AEs) were reported in 47.5% (723/1522) of patients; the most common were neutropenia (16.2%) and leukopenia (7.4%). The rate of treatment discontinuation due to AEs was low (5.9% of all patients in the ribociclib arm). Conclusion. The observational PROSPERITY study provided real-world data from Russia demonstrating ribociclib effectiveness and safety profiles generally comparable to results previously obtained in pivotal clinical trials.
- 21 January 2026
- Published by Alfmed LLC in Medical alphabet
- No. 33
Clinical case: Nivolumab in 3rd line treatment of gastric cancer
- 21 January 2026
- Published by Alfmed LLC in Medical alphabet
- No. 33
Clinical case: Nivolumab in 3rd line treatment of gastric cancer
- Open Access
- 30 December 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (6)
ORCHIDEA: A Retrospective Study of Patient Demographics, Clinical Characteristics, and Adjuvant Therapy Patterns in Stage II–III HR+/HER2– Breast Cancer Within Routine Clinical Practice
Введение. Риск рецидива гормонозависимого HER2-негативного рака молочной железы (HR+ HER2-РМЖ) II–III стадии сохраняется на протяжении многих лет, несмотря на проводимую комплексную терапию. Оценка факторов риска дает возможность интенсифицировать адъювантную гормонотерапию и предотвратить рецидив. Целью исследования ORCHIDEA являлось определение клинических и демографических характеристик российских пациенток с HR+/HER2-РМЖ II и III стадии, а также оценка назначаемых схем адъювантной терапии в реальной клинической практике. Материалы и методы. Ретроспективное наблюдательное исследование проводили на базе 14 исследовательских центров России. В него включали пациенток старше 18 лет с подтвержденным диагнозом HR+/HER2-РМЖ II–III стадии, получавших адъювантную гормонотерапию в период с 01.12.2022 по 01.12.2023. Результаты. В исследование включили 1000 пациенток. Средний возраст составил 61 год. Пациенты со II стадией достигали 76,1 %. Пациентки без поражения лимфоузлов составляли 42,7 %, из них более половины (64,7 %) имели хотя бы один фактор риска рецидива (Т3–4 или Т2 в сочетании с G3 или с G2 и Ki67 ≥ 20 %); пациентки с поражением одного-трех лимфоузлов (N1) составляли 41,6 %, с N2–3 — 15,7 %. Уровень Ki67 ≥ 20 % отмечался у 61,6 % пациенток; степень злокачественности 3 — у 13 %. Большинство пациенток (73,0 %) получали терапию ингибитором ароматазы (ИА), тамоксифеном — 26,0 %, абемациклибом в сочетании с ИА или тамоксифеном — 1 %. Частота назначения химиотерапии составила 54,8 %: 33,4 % пациентов получали неоадъювантную ХТ, 23,9 % — адъювантную ХТ. Выводы. Исследование выявило ключевые характеристики пациенток с HR+/HER2- РМЖ II–III стадии, позволяя выявить группы высокого риска рецидива и определить необходимость интенсификации терапии. Данные работы создают основу для оптимизации подходов к профилактике рецидивов РМЖ в России.
- 30 December 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (6)
Open AccessORCHIDEA: A Retrospective Study of Patient Demographics, Clinical Characteristics, and Adjuvant Therapy Patterns in Stage II–III HR+/HER2– Breast Cancer Within Routine Clinical Practice
Введение. Риск рецидива гормонозависимого HER2-негативного рака молочной железы (HR+ HER2-РМЖ) II–III стадии сохраняется на протяжении многих лет, несмотря на проводимую комплексную терапию. Оценка факторов риска дает возможность интенсифицировать адъювантную гормонотерапию и предотвратить рецидив. Целью исследования ORCHIDEA являлось определение клинических и демографических характеристик российских пациенток с HR+/HER2-РМЖ II и III стадии, а также оценка назначаемых схем адъювантной терапии в реальной клинической практике. Материалы и методы. Ретроспективное наблюдательное исследование проводили на базе 14 исследовательских центров России. В него включали пациенток старше 18 лет с подтвержденным диагнозом HR+/HER2-РМЖ II–III стадии, получавших адъювантную гормонотерапию в период с 01.12.2022 по 01.12.2023. Результаты. В исследование включили 1000 пациенток. Средний возраст составил 61 год. Пациенты со II стадией достигали 76,1 %. Пациентки без поражения лимфоузлов составляли 42,7 %, из них более половины (64,7 %) имели хотя бы один фактор риска рецидива (Т3–4 или Т2 в сочетании с G3 или с G2 и Ki67 ≥ 20 %); пациентки с поражением одного-трех лимфоузлов (N1) составляли 41,6 %, с N2–3 — 15,7 %. Уровень Ki67 ≥ 20 % отмечался у 61,6 % пациенток; степень злокачественности 3 — у 13 %. Большинство пациенток (73,0 %) получали терапию ингибитором ароматазы (ИА), тамоксифеном — 26,0 %, абемациклибом в сочетании с ИА или тамоксифеном — 1 %. Частота назначения химиотерапии составила 54,8 %: 33,4 % пациентов получали неоадъювантную ХТ, 23,9 % — адъювантную ХТ. Выводы. Исследование выявило ключевые характеристики пациенток с HR+/HER2- РМЖ II–III стадии, позволяя выявить группы высокого риска рецидива и определить необходимость интенсификации терапии. Данные работы создают основу для оптимизации подходов к профилактике рецидивов РМЖ в России.
- Open Access
- 4 August 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 24 (3) , 198-204
Peritoneal mesotheioma. Cytoreductive surgery and HIPEC
Background. Peritoneal mesothelioma is a rare, high invasive and aggressive malignant tumor that arises from the mesothelial cells lining the abdominal cavity. Surgery is a primary treatment method for mesothelioma. It allows the removal of macroscopically visible tumor masses, which are often resistant to conventional drug therapy. However, the necessity and appropriateness of a surgical approach should be assessed individually, taking into account the histological subtype of the tumor, the extent of its spread and the presence of associated risk factors. Current research shows that the best long-term results are achieved with a multimodal treatment approach, which may include a combination of surgery, chemotherapy, and radiotherapy. This comprehensive approach allows for more effective management of the disease and improved quality of life of patients.Case report. We present a clinical case of a 59year-old female patient with peritoneal mesothelioma. The patient underwent surgery with intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin and doxorubicin. During a 12-month follow-up, there were no signs of disease progression, which indicates the high effectiveness of the applied approach.Conclusion. The use of cytoreductive surgery and HIPEC demonstrated positive effects in the treatment of peritoneal mesothelioma.
- 4 August 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 24 (3) , 198-204
Open AccessPeritoneal mesotheioma. Cytoreductive surgery and HIPEC
Background. Peritoneal mesothelioma is a rare, high invasive and aggressive malignant tumor that arises from the mesothelial cells lining the abdominal cavity. Surgery is a primary treatment method for mesothelioma. It allows the removal of macroscopically visible tumor masses, which are often resistant to conventional drug therapy. However, the necessity and appropriateness of a surgical approach should be assessed individually, taking into account the histological subtype of the tumor, the extent of its spread and the presence of associated risk factors. Current research shows that the best long-term results are achieved with a multimodal treatment approach, which may include a combination of surgery, chemotherapy, and radiotherapy. This comprehensive approach allows for more effective management of the disease and improved quality of life of patients.Case report. We present a clinical case of a 59year-old female patient with peritoneal mesothelioma. The patient underwent surgery with intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin and doxorubicin. During a 12-month follow-up, there were no signs of disease progression, which indicates the high effectiveness of the applied approach.Conclusion. The use of cytoreductive surgery and HIPEC demonstrated positive effects in the treatment of peritoneal mesothelioma.
- 20 July 2025
- Published by PANORAMA Publishing House in Hirurg (Surgeon)
- No. 4,p. 67-80
Surgical treatment for pleural mesothelioma with hyperthermic intrathoracic chemotherapy: a clinical case
The purpose of the study: to review the combined surgical treatment of patients with malignant pleural mesothelioma using hyperthermic intrapleural chemoperfusion and provide clinical cases of surgical treatment of mesothelioma. Materials and methods. The article provides an overview of surgical options for pleural mesothelioma using hyperthermic intrapleural chemotherapy. Two successful clinical cases of surgical treatment of pleural mesothelioma in the scope of extrapleural pleuropneumonectomy with diaphragm resection and hyperthermic intrapleural chemotherapy are presented. Results. Malignant mesothelioma is a rare neoplasm that develops from mesothelial cells lining body cavities, including the pleura, pericardium, peritoneum, and tunica vaginalis. The incidence of malignant mesothelioma is heterogeneous in different regions of the world. According to some estimates, 28,000-43,000 people die annually from malignant pleural mesothelioma worldwide. Among all mesothelial tumors, the proportion of pleural mesothelioma is more than 2/3. Etiologically, pleural mesothelioma is more often caused by exposure to asbestos. Thoracoscopic biopsy is the most effective way to obtain material for morphological examination. Pleural mesothelioma includes three histological subtypes: epithelioid, sarcomatoid, and mixed/biphasic. Conclusion. Determining the histological subtype of a tumor is crucial for further treatment and prognosis. Recommended mesothelial markers are calretinin, WT1, D2-40 podoplanin), HBME-1, and CK5/6. The treatment of mesothelioma is a complex task. During surgery for mesothelioma, it is necessary to achieve macroscopic complete resection to improve long-term results.
- 20 July 2025
- Published by PANORAMA Publishing House in Hirurg (Surgeon)
- No. 4,p. 67-80
Surgical treatment for pleural mesothelioma with hyperthermic intrathoracic chemotherapy: a clinical case
The purpose of the study: to review the combined surgical treatment of patients with malignant pleural mesothelioma using hyperthermic intrapleural chemoperfusion and provide clinical cases of surgical treatment of mesothelioma. Materials and methods. The article provides an overview of surgical options for pleural mesothelioma using hyperthermic intrapleural chemotherapy. Two successful clinical cases of surgical treatment of pleural mesothelioma in the scope of extrapleural pleuropneumonectomy with diaphragm resection and hyperthermic intrapleural chemotherapy are presented. Results. Malignant mesothelioma is a rare neoplasm that develops from mesothelial cells lining body cavities, including the pleura, pericardium, peritoneum, and tunica vaginalis. The incidence of malignant mesothelioma is heterogeneous in different regions of the world. According to some estimates, 28,000-43,000 people die annually from malignant pleural mesothelioma worldwide. Among all mesothelial tumors, the proportion of pleural mesothelioma is more than 2/3. Etiologically, pleural mesothelioma is more often caused by exposure to asbestos. Thoracoscopic biopsy is the most effective way to obtain material for morphological examination. Pleural mesothelioma includes three histological subtypes: epithelioid, sarcomatoid, and mixed/biphasic. Conclusion. Determining the histological subtype of a tumor is crucial for further treatment and prognosis. Recommended mesothelial markers are calretinin, WT1, D2-40 podoplanin), HBME-1, and CK5/6. The treatment of mesothelioma is a complex task. During surgery for mesothelioma, it is necessary to achieve macroscopic complete resection to improve long-term results.
- 3 July 2025
- Published by Alfmed LLC in Medical alphabet
- No. 11,p. 25-32
Surgery in the treatment of small cell lung cancer
Background. Small cell lung cancer (SCLC) is one of the most aggressive forms of lung tumors. Currently, there are ongoing discussions about the role of surgery in the treatment of patients with SCLC.The purpose of the study: does surgery improve prognosis in patients with small-cell lung cancer (SCLC)?Methods. The material for the study was 7549 patients with lung cancer diagnosed in Ugra from 2002 to 2022. 71 SCLC with stage I to III undergoing surgical resection were enrolled. Lobectomy was performed in 49 patients, pneumonectomy in 22. Systematic nodal dissection (SND) was performed in 59 patients (83.1 %).Results. In stage I, the ten-year overall survival rate was 65.8 %, in stage II – 33.2 %, in stage III – 14.4 % (p=0,001). Remote results of surgical treatment of SCLC had a significant dependence on the state of regional lymph nodes: with N 0, the 10-year OS was 53.1 %, with N 1 the 10-year OS was 30.6 %, with N 2–15.1 % (p=0,003). Ten-year OS with SND was significantly exceeded other dissections on the lymphatic collector to 42.0 %, while with sampling nodal dissection the 10-year OS was only 20.0 % (p=0,028).Conclusion. Good remote results in patients with stage I and II SCLC indicate the need to include surgery in the complex treatment of patients with SCLC. The optimal volume of surgery is lobectomy with systematic nodal dissection. Surgery can be performed in patients with stage IIIA and IIIB SCLC in case of tumor regression after induction chemoor chemoradiotherapy, as well as in case of life-threatening complications. Prospective studies are required to determine the indications for surgery in this cohort of patients.
- 3 July 2025
- Published by Alfmed LLC in Medical alphabet
- No. 11,p. 25-32
Surgery in the treatment of small cell lung cancer
Background. Small cell lung cancer (SCLC) is one of the most aggressive forms of lung tumors. Currently, there are ongoing discussions about the role of surgery in the treatment of patients with SCLC.The purpose of the study: does surgery improve prognosis in patients with small-cell lung cancer (SCLC)?Methods. The material for the study was 7549 patients with lung cancer diagnosed in Ugra from 2002 to 2022. 71 SCLC with stage I to III undergoing surgical resection were enrolled. Lobectomy was performed in 49 patients, pneumonectomy in 22. Systematic nodal dissection (SND) was performed in 59 patients (83.1 %).Results. In stage I, the ten-year overall survival rate was 65.8 %, in stage II – 33.2 %, in stage III – 14.4 % (p=0,001). Remote results of surgical treatment of SCLC had a significant dependence on the state of regional lymph nodes: with N 0, the 10-year OS was 53.1 %, with N 1 the 10-year OS was 30.6 %, with N 2–15.1 % (p=0,003). Ten-year OS with SND was significantly exceeded other dissections on the lymphatic collector to 42.0 %, while with sampling nodal dissection the 10-year OS was only 20.0 % (p=0,028).Conclusion. Good remote results in patients with stage I and II SCLC indicate the need to include surgery in the complex treatment of patients with SCLC. The optimal volume of surgery is lobectomy with systematic nodal dissection. Surgery can be performed in patients with stage IIIA and IIIB SCLC in case of tumor regression after induction chemoor chemoradiotherapy, as well as in case of life-threatening complications. Prospective studies are required to determine the indications for surgery in this cohort of patients.
- 18 March 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 24 (1)
A case of tracheal chondrosarcoma
Background. Chondrosarcoma of the trachea is an extremely rare malignant tumor, accounting for only 0.1 % of all tracheal tumors. It is believed that chondrosarcoma arises from malignant degeneration in mesenchymal pluripotent cells of cartilage tissue, ossified cartilage, and enchondromas. Chondrosarcoma of the trachea is the least-studied tumor, with only 35 cases described in the literature from 1959 to 2020. Surgery with R0 resection remains the gold standard treatment of tracheal chondrosarcoma. The median age of patients at the time of diagnosis was 68 years, and 91 % were male. The most common symptoms at the initial visit were dyspnea (up to 80 % of cases). Tumors located in the proximal third of the trachea were observed in 54 % of cases, while tumors in the distal third of the trachea were found in 29 % of cases. Low-grade tumors (g1) were the most common (54 %). Computed tomography of the chest is considered the gold standard for the detection of tracheal tumors. Purpose: To demonstrate a successful case of treatment of tracheal chondrosarcoma. Case presentation. A 67-year-old male patient was diagnosed with a tracheal tumor. On 04.07.2022, surgical treatment was performed: circular resection of the 2nd, 3rd, and 4th tracheal rings with lymph node dissection of the regional paratracheal lymph nodes R0. The postoperative period was uneventful. Adjuvant therapy was not given. At the 2-year follow-up, no anastomotic complications were reported. Conclusion. To date, circular resection of the trachea (R0) with end-to-end tracheal anastomosis is the gold standard for treating tracheal chondrosarcoma. this approach was performed in 77 % of cases with the median follow-up time of more than 30 months and relapse rate of only 6 %. It should be noted that adjuvant chemotherapy was not used in these cases due to the extremely low sensitivity of the tumor to chemotherapy drugs.
- 18 March 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 24 (1)
A case of tracheal chondrosarcoma
Background. Chondrosarcoma of the trachea is an extremely rare malignant tumor, accounting for only 0.1 % of all tracheal tumors. It is believed that chondrosarcoma arises from malignant degeneration in mesenchymal pluripotent cells of cartilage tissue, ossified cartilage, and enchondromas. Chondrosarcoma of the trachea is the least-studied tumor, with only 35 cases described in the literature from 1959 to 2020. Surgery with R0 resection remains the gold standard treatment of tracheal chondrosarcoma. The median age of patients at the time of diagnosis was 68 years, and 91 % were male. The most common symptoms at the initial visit were dyspnea (up to 80 % of cases). Tumors located in the proximal third of the trachea were observed in 54 % of cases, while tumors in the distal third of the trachea were found in 29 % of cases. Low-grade tumors (g1) were the most common (54 %). Computed tomography of the chest is considered the gold standard for the detection of tracheal tumors. Purpose: To demonstrate a successful case of treatment of tracheal chondrosarcoma. Case presentation. A 67-year-old male patient was diagnosed with a tracheal tumor. On 04.07.2022, surgical treatment was performed: circular resection of the 2nd, 3rd, and 4th tracheal rings with lymph node dissection of the regional paratracheal lymph nodes R0. The postoperative period was uneventful. Adjuvant therapy was not given. At the 2-year follow-up, no anastomotic complications were reported. Conclusion. To date, circular resection of the trachea (R0) with end-to-end tracheal anastomosis is the gold standard for treating tracheal chondrosarcoma. this approach was performed in 77 % of cases with the median follow-up time of more than 30 months and relapse rate of only 6 %. It should be noted that adjuvant chemotherapy was not used in these cases due to the extremely low sensitivity of the tumor to chemotherapy drugs.
- Open Access
- 3 March 2022
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 21 (1) , 85-90
Bronchoplatic surgery in the treatment of patients with nonsmall cell lung cancer
Aim. To study the effect of organ-preserving bronchoplastic surgery on long-term treatment outcomes of patients with non-small cell lung cancer (NSCLC ).Material and Methods. The long-term results of surgical treatment of 740 patients with stage I–III NSCLC , who were treated in Ugra from 2002 to 2015, were analyzed. Lobectomy and bilobectomy were performed in 477 patients, and pneumonectomy was performed in 263 patients. Thirty-two patients underwent bronchoplastic lobectomy and bilobectomy. Intraoperative pathological frozen sections of lymph nodes (# 12) of the remaining lobe of the lung were examined in all patients. If metastases in these lymph nodes were not detected, we performed bronchoplastic lobectomy. If metastases in lymph nodes of the remaining lobe were detected, we performed pneumonectomy. The median age of the patients (only male patients) was 55.3 ± 9.9 years. In 19 (59.4 %) patients, sleeve resections were performed on the right side and in 13 (40.6 %) patients, these resections were performed on the left side. There were 15 bronchoplastic lobectomies of type A, 9 of type B, 4 of type C, and 4 of type D. Sleeve resection of the pulmonary artery was performed in 4 patients. In 16 cases (50.0 %), there were no regional metastases (pN0). In 10 (31.3 %) cases, there was pN1, in six – pN2 (18.7 %).Results. There were no cases of postoperative death. Late complications (asymptomatic bronchial stenosis) occurred in 3 (9.4 %) patients. Long-term treatment outcomes were better in patients who underwent organ-preserving bronchoplastic surgery than in patients who underwent pneumonectomy. Median survival was 66 months after bronchoplastic lobectomies and 34 months after pneumonectomies (p=0.01). The 5- and 10-year survival rates in patients who underwent bronchoplastic lobectomies were 52.9 % and 36.2 %, respectively. The corresponding values in patients who underwent pneumonectomies were 38.0 % and 31.9 %, respectively.Conclusion. Organ-preserving bronchoplastic surgery compared to pneumonectomy does not worsen long-term outcomes in patients with NSCLC .
- 3 March 2022
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 21 (1) , 85-90
Open AccessBronchoplatic surgery in the treatment of patients with nonsmall cell lung cancer
Aim. To study the effect of organ-preserving bronchoplastic surgery on long-term treatment outcomes of patients with non-small cell lung cancer (NSCLC ).Material and Methods. The long-term results of surgical treatment of 740 patients with stage I–III NSCLC , who were treated in Ugra from 2002 to 2015, were analyzed. Lobectomy and bilobectomy were performed in 477 patients, and pneumonectomy was performed in 263 patients. Thirty-two patients underwent bronchoplastic lobectomy and bilobectomy. Intraoperative pathological frozen sections of lymph nodes (# 12) of the remaining lobe of the lung were examined in all patients. If metastases in these lymph nodes were not detected, we performed bronchoplastic lobectomy. If metastases in lymph nodes of the remaining lobe were detected, we performed pneumonectomy. The median age of the patients (only male patients) was 55.3 ± 9.9 years. In 19 (59.4 %) patients, sleeve resections were performed on the right side and in 13 (40.6 %) patients, these resections were performed on the left side. There were 15 bronchoplastic lobectomies of type A, 9 of type B, 4 of type C, and 4 of type D. Sleeve resection of the pulmonary artery was performed in 4 patients. In 16 cases (50.0 %), there were no regional metastases (pN0). In 10 (31.3 %) cases, there was pN1, in six – pN2 (18.7 %).Results. There were no cases of postoperative death. Late complications (asymptomatic bronchial stenosis) occurred in 3 (9.4 %) patients. Long-term treatment outcomes were better in patients who underwent organ-preserving bronchoplastic surgery than in patients who underwent pneumonectomy. Median survival was 66 months after bronchoplastic lobectomies and 34 months after pneumonectomies (p=0.01). The 5- and 10-year survival rates in patients who underwent bronchoplastic lobectomies were 52.9 % and 36.2 %, respectively. The corresponding values in patients who underwent pneumonectomies were 38.0 % and 31.9 %, respectively.Conclusion. Organ-preserving bronchoplastic surgery compared to pneumonectomy does not worsen long-term outcomes in patients with NSCLC .
- Open Access
- 31 October 2021
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 20 (5) , 31-40
LOBE-SPECIFIC METASTASIS IN NON-SMALL CELL LUNG CANCER
Aim: to identify the pathways of lymph node metastases in non-small cell lung cancer (NSCLC).Material and Methods. The frequency of mediastinal lymph node metastases and treatment outcomes were analyzed in 327 patients with stage I–III non-small cell lung carcinoma (NSCLC), who underwent lung resection with systematic lymph node dissection (SLND) between 2007 and 2011.Results. In cases with tumor location in any lobe of the right lung, metastasis occurred in the superior and inferior mediastinal lymph nodes. In left-side tumors, the main pathways of lymphatic spread of tumors were superior and inferior mediastinal nodes as well as aortic lymph nodes. Left lower lobe tumors metastasized most often to inferior mediastinal lymph nodes. Skip metastases were observed at any location of the tumor. Routine examination of all ipsilateral mediastinal lymph nodes overstaged NSCLC in 19.5 % of cases. The overall 5-and 10-year survival rates in patients with stage I–III NSCLC with SND were 61.5 % and 49.2 %, respectively. The median survival time was 103 months.Conclusion. Despite typical metastatic patterns of mediastinal lymph nodes in patients with NSCLC, non-specific metastasis was observed at any location of the tumor, which required mandatory systematic nodal dissection.
- 31 October 2021
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 20 (5) , 31-40
Open AccessLOBE-SPECIFIC METASTASIS IN NON-SMALL CELL LUNG CANCER
Aim: to identify the pathways of lymph node metastases in non-small cell lung cancer (NSCLC).Material and Methods. The frequency of mediastinal lymph node metastases and treatment outcomes were analyzed in 327 patients with stage I–III non-small cell lung carcinoma (NSCLC), who underwent lung resection with systematic lymph node dissection (SLND) between 2007 and 2011.Results. In cases with tumor location in any lobe of the right lung, metastasis occurred in the superior and inferior mediastinal lymph nodes. In left-side tumors, the main pathways of lymphatic spread of tumors were superior and inferior mediastinal nodes as well as aortic lymph nodes. Left lower lobe tumors metastasized most often to inferior mediastinal lymph nodes. Skip metastases were observed at any location of the tumor. Routine examination of all ipsilateral mediastinal lymph nodes overstaged NSCLC in 19.5 % of cases. The overall 5-and 10-year survival rates in patients with stage I–III NSCLC with SND were 61.5 % and 49.2 %, respectively. The median survival time was 103 months.Conclusion. Despite typical metastatic patterns of mediastinal lymph nodes in patients with NSCLC, non-specific metastasis was observed at any location of the tumor, which required mandatory systematic nodal dissection.